Activist Palogic Raises Stake to 7.1% and Demands Business Plan, R&D Cost Split
HCAT sits 78% above its 52-week low of $0.955.
Summary
Activist investor Palogic Value Management raised its stake to 7.1% and sent a letter demanding a clear business plan, separated R&D costs, and enhanced revenue disclosures after the Vitalware sale.
Key Events · Ownership and Investor Activity · HCAT
-
Palogic Raises Stake to 7.1%
Palogic Value Management increased its beneficial ownership to 5,374,949 shares, or 7.1% of the class, up from 6.7% disclosed in June 2026.
-
Activist Letter Demands Business Plan
On September 4, 2026, Palogic sent a letter to the board requesting a forward-looking business plan, separated R&D costs, enhanced revenue and retention disclosures, and answers on capital allocation.
-
Open Market Purchases Total 451,720 Shares
Annex A shows Palogic bought 451,720 shares between August 6 and September 1, 2026, at prices from $1.53 to $1.76 per share, spending roughly $750,000.
-
Post-Vitalware Balance Sheet Strength
Palogic applauded the $147 million Vitalware sale, noting it transitioned the company from net-debt to a well-capitalized, net-cash balance sheet.
Analysis · HCAT · Technology
Palogic Value Management increased its stake from 6.7% to 7.1% and sent a pointed letter to the board demanding a forward-looking business plan, separated R&D costs, and granular revenue disclosures. The letter follows the $147 million Vitalware sale that left the company net-cash, and Palogic argues the market undervalues the remaining application business. The activist is pressing for transparency on capital allocation and a path to profitable growth, which could pressure management to change reporting and strategy.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1973 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCAT was trading at $1.70 on NASDAQ in the Technology sector, with a market capitalization of approximately $127.9M. The 52-week trading range was $0.96 to $3.62. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.